Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach
Authors:
- 30 June 2023
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (10) , 5987-6000
Abstract
All biological tissues and bodily fluids include the autacoid adenosine. The P1 class of purinergic receptors includes adenosine receptors. Four distinct G-protein-coupled receptors on the cellular membrane mediate the effects of adenosine, whose cytoplasmic content is regulated by producing/degrading enzymes and nucleoside transporters. A2A receptor has received a great deal of attention in recent years because it has a wide range of potential therapeutic uses. A2B and, more significantly, A2A receptors regulate numerous physiological mechanisms in the central nervous system (CNS). The inferior targetability of A2B receptors towards adenosine points that they might portray a promising medicinal target since they are triggered only under pharmacological circumstances (when adenosine levels rise up to micromolar concentrations). The accessibility of specific ligands for A2B receptors would permit the exploration of such a theory. A2A receptors mediate both potentially neurotoxic and neuroprotective actions. Hence, it is debatable to what extent they play a role in neurodegenerative illnesses. However, A2A receptor blockers have demonstrated clear antiparkinsonian consequences, and a significant attraction exists in the role of A2A receptors in other neurodegenerative disorders. Amyloid peptide extracellular accumulation and tau hyperphosphorylation are the pathogenic components of AD that lead to neuronal cell death, cognitive impairment, and memory loss. Interestingly, in vitro and in vivo research has shown that A2A adenosine receptor antagonists may block each of these clinical symptoms, offering a crucial new approach to combat a condition for which, regrettably, only symptomatic medications are currently available. At least two requirements must be met to determine whether such receptors are a target for diseases of the CNS: a complete understanding of the mechanisms governing A2A-dependent processes and the availability of ligands that can distinguish between the various receptor populations. This review concisely summarises the biological effects mediated by A2A adenosine receptors in neurodegenerative disorders and discusses the chemical characteristics of A2A adenosine receptor antagonists undergoing clinical trials. Graphical Abstract Selective A2A receptor blocker against neurodegenerative disordersKeywords
This publication has 118 references indexed in Scilit:
- Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand EfficacyMolecular Pharmacology, 2013
- Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's DiseaseThe Journal of Neuroscience, 2012
- Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injuryReviews in the Neurosciences, 2011
- To use or not to use: an update on licit and illicit ketamine useSubstance Abuse and Rehabilitation, 2011
- Amyotrophic lateral sclerosisThe Lancet, 2011
- Introduction to Adenosine Receptors as Therapeutic Targets2009
- Adenosine A2A receptors in Parkinson’s disease treatmentPurinergic Signalling, 2008
- Adenosine A2A Receptors Are Essential for Long-Term Potentiation of NMDA-EPSCs at Hippocampal Mossy Fiber SynapsesNeuron, 2008
- TMP21 is a presenilin complex component that modulates γ-secretase but not ɛ-secretase activityNature, 2006
- Facilitation of noradrenaline release by activation of adenosine A2A receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail arteryCardiovascular Research, 2004